From CBC News:
Some doctors in Canada are worried about the side-effects of an anti-obesity drug that is expected to hit the market in the U.S. by spring 2008.
Known in Europe as Acomplia and generically as rimonabant, the drug helps people to lose weight, controls Type 2 diabetes, raises high-density lipoprotein or HDL "good" cholesterol and tells the brain to stop craving food and cigarettes. ...more
Links to the latest news in the world of pharmacy with a focus on items most relevant to Canadian pharmacists or others that are interested in Canadian pharmacies. This includes news about Canadian pharmacy seen in the mainstream media on topics such as new drug information and the international pharmacy industry.
Wednesday, January 03, 2007
Anti-obesity drug no magic bullet
Here's an update regarding Acomplia from CBC. They may state it's not a magic bullet, but if it brings in $5 billion per year in the U.S. alone, it would make it one of the biggest selling drugs in the world.
No comments:
Post a Comment